determination and the implementation of preventive, diagnostic or therapeutic medical
strategies. However, the ESC Guidelines do not override in any way whatsoever the individual …

The task of developing ESC Guidelines covers not only the integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute
respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic …

Background The role of fibrinolytic therapy in patients with intermediate-risk pulmonary
embolism is controversial. Methods In a randomized, double-blind trial, we compared …

Background— Thrombosis is the common pathology underlying ischemic heart disease,
ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study …

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected …

Pulmonary embolism (PE) remains a major contributor to global disease burden. Risk-adapted
treatment and follow-up contributes to a favorable outcome. Age-adjusted cutoff levels …

Aims Pulmonary embolism (PE) is the third most common cardiovascular cause of death;
systemic thrombolysis is potentially lifesaving treatment in patients presenting with …

Background : The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is
unknown. Objectives : This study investigated the long-term prognosis of patients with …

A number of ECG abnormalities can be observed in the acute phase of pulmonary embolism
(PE). Their prognostic value has not yet been systematically studied in large patient …